RESEARCH ARTICLE

Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis

Sikarin Upala1,2, Anawin Sanguankeo1,2* and Nitipong Permpalung1

Abstract

Background: A number of observational studies have found an association between low vitamin D levels and risk of sepsis. We conducted a systematic review and meta-analysis to determine the overall estimate of risk.

Methods: This was a systematic review and meta-analysis conducted by online searches (CENTRAL, PubMed/MEDLINE, and EMBASE) was registered in PROSPERO (CRD42014014767). Primary outcome was incidence, prevalence, relative risk or odds ratio of having sepsis or bloodstream infection between patients with vitamin D deficiency and controls.

Results: The initial search yielded 647 articles. Twenty-one articles underwent full-length review and data were extracted from 10 observational studies. Pooled odds ratio of sepsis in participants with vitamin D deficiency was 1.78 (95 % confidence interval [CI] = 1.55 to 2.03, p < 0.01) compared with controls in studies that reported participant numbers and was 1.45 (95 % CI = 1.26 to 1.66, p < 0.01) in studies that reported an adjusted odds ratio of vitamin D deficiency for developing sepsis. Statistical between-study heterogeneity was low (I² = 0 % and 5 %, respectively). Standardized mean difference of 25-hydroxyvitamin D levels in patients with sepsis and controls was −0.24 (95 % CI = −0.49 to 0.00, p = 0.05) and lower in the sepsis group compared with non-sepsis or control participants. The statistical between-study heterogeneity (I²) was 0 %.

Conclusion: Vitamin D deficiency were associated with an increased susceptibility of sepsis.

Keywords: Vitamin D deficiency, Sepsis, Systematic review, Meta-analysis

Background

Vitamin D or cholecalciferol is a fat-soluble vitamin primarily synthesized from 7-dehydroxycholesterol in the skin by ultraviolet radiation [1]. A previous study showed that serum concentrations of 25-hydroxyvitamin D (25(OH)D) were related to geography and season [2]. Lower values were observed in the winter, whereas higher values were observed in the summer [3]. Additionally, a closer distance to the equator was associated with a lower magnitude of seasonal variation of 25(OH)D levels [4, 5]. This variation in vitamin D is resemblance to that in infection as the incidence and mortality of sepsis is highest during the winter months and is associated with increased respiratory illnesses [6]. The association of 25(OH)D deficiency and infections is likely due to the pleiotropic effects of 25(OH)D on human immunity, including T-cell proliferation, immunoglobulin class-switching, and cytokine release [7]. 1,25-dihydroxy vitamin D3 (1,25 (OH)2D) directly enhances signaling of the innate immune system to increase the production of antimicrobial peptides (AMP), such as cathelicidin and LL-37, its activated form [8]. Based on in vitro studies, LL-37 is active against various pathogens including Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes, Staphylococcus epidermidis, Staphylococcus aureus, and vancomycin-resistant enterococci [9]. The human cathelicidin (LL-37) has broad anti-microbial activities against bacteria, viruses and fungi.

A number of observational studies have found an association between low vitamin D levels and risk of sepsis. However, the effect of 25(OH)D in different infections is unclear and sepsis patients can have a heterogeneous...
mixture of pathogens and infected organ systems. The objective of this systematic review and meta-analysis of observational studies was to comprehensively determine the strength of association between vitamin D deficiency and sepsis in hospitalized patients, compared with optimal vitamin D group. The secondary objective was to determine any difference in 25(OH)D level between sepsis patients and controls.

Methods
This systematic review and meta-analysis was conducted and reported according to established guidelines for meta-analysis of observational studies [10] and was registered in PROSPERO (registration number: CRD42014014767).

Criteria for selection of studies for review

Types of studies
All published observational studies including prospective cohort, retrospective cohort, case-control, and cross-sectional studies, that evaluated association between levels of vitamin D (25(OH)D or 1,25-dihydroxyvitamin D [1,25(OH)2D]) or prevalence of vitamin D deficiency and the incidence or prevalence of sepsis during hospitalization were included. Reviews, case reports, letters, commentaries, abstracts, and unpublished studies were not included.

Types of participants
Participants of 18 years of age or older who were hospitalized and had vitamin D levels (25(OH)D or 1,25(OH)2D) measured before or during hospitalization were included.

Types of risk factors
We included all studies that defined vitamin D deficiency as a 25(OH)D level less than 20 ng/mL (50 nmol/L) [11] or defined an optimal level or vitamin D sufficiency as a 25(OH)D concentration greater than 30 ng/mL (75 nmol/L). The latter definition was used to characterize the optimal group. We reported definition of vitamin D deficiency and cut-off of 25(OH)D.

Types of outcome measures
Primary outcomes were incidence, prevalence, relative risk or odds ratio of having sepsis or bloodstream infection between patients with vitamin D deficiency and controls. We included studies that defined sepsis as a systemic inflammatory response syndrome caused by infection, or having International Classification of Diseases (ICD)-9 codes 038.0–038.9, 995.91, 995.92, or bloodstream infection. Studies that did not define sepsis were excluded. A difference in the levels of 25(OH)D between patients with sepsis and control was the secondary outcome.

Search methods for identification of studies
A.S. and S.U. independently searched published studies indexed in the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, PubMed/MEDLINE, and EMBASE from database inception to October 2014. References of selected retrieved articles were also examined. Search terms that were used included: vitamin D, 25-hydroxyvitamin D, 25(OH)D, vitamin D2, vitamin D3, ergocalciferol, cholecalciferol, calcidiol, calcifediol, calcitriol, sepsis, septicemia, septic shock. Search terms that were used are detailed in Additional file 1.

Data collection and analysis
Selection of studies
A.S. and S.U. independently reviewed the titles and abstracts of all citations identified. After all studies were abstracted, face-to-face data comparisons between investigators were conducted to ensure completeness and reliability. The inclusion criteria were independently applied to all identified studies. Only full-text articles in English were included in the meta-analysis. Differing decisions were resolved by consensus.

Data extraction and management
Full-text versions of potentially relevant papers identified in the initial screening were retrieved. Data concerning study design (cross-sectional, case-control, prospective cohort, retrospective cohort), participant characteristics (age, sex, settings), vitamin D levels, participants with vitamin D deficiency, and outcome measures (definition of sepsis, number of participants with sepsis, mortality rates, odds ratio or risk ratio) were independently extracted. We contacted authors of the primary reports to request any unpublished data. If the authors did not reply, we used the available data for our analyses.

Assessment of bias risk
The quality of observational studies was evaluated by two investigators (A.S. and S.U.) using the Newcastle-Ottawa quality assessment scale [12]. The NOS is based on three major components: selection of the study groups (0–4 stars in cohort study and 0-5 stars in cross-sectional study), comparability of cases and controls by controlling for relevant factors (0–2 stars), and ascertainment of exposure/outcome (0–3 stars). A study awarded 7 stars or more is considered a high-quality study, 4-6 stars is considered a moderate-quality study, and 0-3 stars is considered a poor-quality study. We excluded any studies that had poor quality from the meta-analysis.

Statistical methods
Data analysis was performed using Review Manager 5.3 software from The Cochrane Collaboration. We reported...
the pooled effect estimate (odds ratio) of sepsis comparing between vitamin D deficiency and optimal vitamin D groups. We also reported standardized mean difference of 25(OH)D levels between sepsis and control groups using a fixed effects model and inverse variance method. The heterogeneity of effect size estimates across these studies was quantified using the $I^2$ statistic index and Cochran Q test [13]. Sensitivity analysis was conducted using random effects model. Publication bias was assessed visually using funnel plots of standard error vs odds ratio in the meta-analysis that included five or more studies [14].

**Results**

**Description of included studies**

The initial search yielded 647 articles (Fig. 1), of which 626 articles were excluded because they were not observational studies, participants did not have sepsis outcome, did not have vitamin D deficiency or vitamin D levels data, or were in a language other than English. A total of 21 articles underwent full-length review. Data were extracted from 10 observational studies [15–24] involving 33,810 participants. All extracted studies were included in the meta-analysis. The characteristics of the extracted studies are outlined in Table 1.

Five studies defined vitamin D deficiency as 25(OH)D ≤15 ng/mL [18, 19, 21, 22, 24] and four studies defined as 25(OH)D ≤20 ng/mL [16, 17, 20, 23]. Only one study measured serum 1,25(OH)D$_2$ and compared between sepsis and control groups [16]. In most studies, serum were drawn within 7-365 days before admission. Assays using for serum vitamin D measurement were ELISA, radioimmunoassay, scintillation proximity assay, tandem mass spectrometry, and chemiluminescence assay.

**Quality assessment**

Quality assessment scores using the Newcastle-Ottawa Scale tool for observational studies are summarized in Table 2 and Table 3. Cross-sectional studies had a total score of 6-7 (selection scale of 2-3, comparability scale of 0-2, and exposure scale of 3). Cohort studies had a total score of 7-9 (selection scale of 4, comparability scale of 0-2, and exposure scale of 3).
Table 1: Characteristics of included studies

| Study       | Design         | Population characteristics                                                                 | Age (Mean ± SD) | Vitamin D cut-off (ng/mL) | Assay                  | Participants (n) | Time measure | 25(OH)D (ng/mL) | 1,25(OH)D2 (ng/mL) |
|-------------|----------------|-------------------------------------------------------------------------------------------|-----------------|---------------------------|-----------------------|------------------|-------------|----------------|-------------------|
| Jeng 2009 [15] | Cross-sectional | Subjects in ICU with and without sepsis, and healthy controls between 1999 and 2006        | 54.0 ± 17.1     | Insufficiency (<30)       | ELISA                 | Total 70         | During hospitalization | 16.0 ± 8.5     | 16.2 ± 7.2       |
| Müllner 2000 [16] | Cross-sectional | Patients admitted to MICU of the Basel University Hospitals                               | 57 ± 15         | Subnormal (<20)           | Radioimmunoassay; 1,25(OH)D2, Scintillation proximity assay | Total 101        | First 24 h, day 2 of discharge | 6.3 ± 5.2       | 8.8 ± 7.7        |
| Su 2013 [17] | Cross-sectional | Patients admitted to ICU in Army Hospital in 2011                                           | 57 ± 19         | Deficiency (<20)          | High performance liquid chromatography and tandem mass spectrometry | Total 156        | Within 24 h of ICU admission | 0.91 ± 0.24a    | 0.97 ± 0.22a     |
| Braun 2012 [18] | Retrospective cohort | Patients aged 218 years who were admitted to BWH and MGH between 1997 and 2009            | 63.0 ± 17.2     | Deficiency (<15)          |                      | Total 1,325       | 7 days before and after critical care initiation | 18.2 ± 13.7     | 9.2 ± 12.3       |
| Braun 2011 [19] | Retrospective cohort | Patients aged 218 years who were admitted to BWH and MGH between 1997 and 2009            | 64.9 ± 16.6     | Deficiency (<15)          |                      | Total 2,399       | 7-365 days before admission | 26.4 ± 15.2     | 7.3 ± 12.1       |
| Flynn 2012 [20] | Prospective cohort study | Participants aged 218 years who were admitted to ICU 248 h for between 2010 -2011        | 56 ± 20         | Deficiency (<20)          |                      | Total 66         | On admission and every 7 days during hospitalization | -               | -               |
| Jovanovich 2014 [21] | Retrospective cohort | Hospitalized participants from hospitals and clinics from 2008-2010                     | 60 ± 17         | Deficiency (<15)          | Radioimmunoassay      | Total 132        | 3-15 months before admission | 70.1 ± 62.2 (79.6) | 79.3 ± 71.1 (88.1) |
| Moromizato 2013 [22] | Retrospective cohort | Patients aged 218 years who were admitted to BWH and MGH between 1998 and 2011           | 65.9 ± 16.1     | Deficiency (<15)          | Chemiluminescence assay, radioimmunoassay, or mass spectroscopy | Total 3,386       | 7-365 days before admission | 29.4 ± 15.5     | -               |
| Quraishi 2013 [23] | Retrospective cohort | Patients aged 218 years who were admitted to BWH and                                      | 61 ± 18         | Deficiency (<20)          | Chemiluminescence assay, radioimmunoassay, | Total 2,135       | 7-365 days before admission | 25 ± 17         | -               |
| Study | Design | Setting | Age | Cause of Infection | Deficiency (≤15) | Insufficiency (15–30) | Sufficiency (≥30) | Methodology | Mean (SD) or Median (IQR) | Number |
|-------|--------|---------|-----|-------------------|-----------------|----------------------|-----------------|-------------|----------------------|---------|
| Lange 2013 [24] | Retrospective cohort | MGH between 1993 and 2011 | ≥18 years | Community-acquired bloodstream infection | 5,241 | 8,679 | 9,683 | Chemiluminescence assay, radioimmunoassay, or mass spectroscopy | 23,603 | 7-365 days before admission | 27.9 (15.1) | - |
| Study (Year) | Selection | Justified sample size | Ascertainment of exposure | Comparable non-respondents rate between two groups | Comparability of different samples on the basis of the design or analysis | Outcome | Appropriate statistical test | Total |
|--------------|-----------|-----------------------|--------------------------|-----------------------------------------------|-----------------------------------------------|---------|----------------------------|-------|
| Jeng 2009    | **        | *                     | *                        | *                                             | **                                             | *       | *                          | 7     |
| Muller 2000  | *         | **                    |                          |                                               | **                                             | *       |                            | 6     |
| Su 2013      | *         | **                    |                          |                                               | **                                             | *       |                            | 6     |
| Study (Year) | Selection | Representativeness of the sample | Non-expose group from same community | Outcome of interest was not present at start of study | Validated measurement tool | Comparability | Comparability of different samples on the basis of the design or analysis | Outcome | Assessment of outcome | Follow up ≥1 month | Adequacy of follow up |
|-------------|-----------|----------------------------------|---------------------------------------|-----------------------------------------------|--------------------------|--------------|------------------------------------------------------------------|--------|----------------------|----------------------|---------------------|
| Braun 2012  | *         | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      |                      | 9                   |
| Braun 2011  | *         | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      | **                   | 9                   |
| Flynn 2012  | *         | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      |                      | 7                   |
| Jovanovich 2014 | *       | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      | *                    | 9                   |
| Moromizato 2013 | *       | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      | *                    | 9                   |
| Quraishi 2013 | *         | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      | *                    | 9                   |
| Lange 2013  | *         | *                                | *                                     | *                                             | *                        | *            |                                                                 |        |                      | *                    | 9                   |
Quantitative results (meta-analysis)
The meta-analysis was performed using the fixed effects model (Fig. 2, 3, 4). It revealed that the pooled odds ratio of sepsis in participants with vitamin D deficiency compared with controls was 1.78 (95% confidence interval [CI] = 1.55 to 2.03, p < 0.01) in studies that reported the number of participants with sepsis in vitamin D deficiency and control groups. In studies that reported an adjusted odds ratio of vitamin D deficiency for developing sepsis as an outcome, the pooled OR was 1.45 (95% CI = 1.26 to 1.66, p < 0.01). The statistical between-study heterogeneity was low with an $I^2$ of 0% (Fig. 2) and 5% (Fig. 3), respectively. Fig. 4 shows the standardized mean difference (SMD) of 25(OH)D levels in patients with sepsis and controls was $-0.24$ (95% CI = $-0.49$ to 0.00, $p = 0.05$) and lower in the sepsis group compared with non-sepsis or control participants. The statistical between-study heterogeneity ($I^2$) was 0%.

Sensitivity analysis
Sensitivity analysis was performed using the random effects model rather than the fixed effects model. The result of the direction of point estimate and statistical difference were not different from the main results.

Meta-regression and subgroup analysis
Meta-regression and subgroup analysis were not performed because the between-study heterogeneity was minimal.

Publication bias analysis
Potential publication bias was assessed by funnel plot of standard error vs odds ratio on the impact of vitamin D deficiency on sepsis (Fig. 5). It revealed a symmetrical distribution of included studies and did not show potential publication bias.
Discussion

This systematic review and meta-analysis assessed the association between vitamin D deficiency, serum 25(OH)D level and sepsis. We observed that patients with vitamin D deficiency (25(OH)D < 15–20 ng/mL) measuring before or during hospitalization have higher odds of sepsis compared to individuals without vitamin D deficiency. We did not find a significant difference of 25(OH)D level between patients who had and did not have sepsis.

Low serum 25(OH)D levels are a common problem in the United States. Based on data from the US National Health and Nutrition Examination Survey (NHANES) in 2001–2006, two-thirds of the population had sufficient vitamin D. About one-quarter were at risk of vitamin D inadequacy, and 8 % were at risk of vitamin D deficiency [25]. The results of the current study reveal a statistically significant increased odds of vitamin D deficiency among septic patients. This meta-analysis finding is in agreement with other critical care studies’ findings. They revealed that low serum concentrations of 25(OH)D was associated with adverse clinical outcomes, including increased mortality rate, increased length of hospital stay, and acute kidney injury in a critical care setting not limited to severe infection and sepsis [26–28]. There were also evidences that deficiency in 25(OH)D and 1,25(OH)₂D were significant predictors of 30-day mortality in septic patients [29, 30]. A pathophysiology that underlies cause of sepsis in vitamin D deficiency could be due to innate immune dysfunction [31]. Moreover, a reduction in 1,25(OH)₂D at the tissue level may lower its pleiotropic effects on immune regulation, mucosal and endothelial function [32, 33].

Many randomized clinical studies did not find benefits on severe infections or sepsis after vitamin D normalization in vitamin D deficient patients [34–37]. The reason could be due to underpowered numbers, low dosages or short duration of supplementation. In most recent clinical trial of 475 patients with vitamin D deficiency [38], administration of high-dose vitamin D3 compared with placebo did not
reduce hospital length of stay, hospital mortality, or 6-month mortality. However, hospital-mortality and mortality rates in this study were significantly lower in the severe vitamin D deficiency subgroup (25-hydroxyvitamin D level less than 12 ng/mL). Further clinical trial exploring effects of vitamin D supplementation on severe infection or sepsis in severe vitamin D deficiency patients is needed.

The results of this study should be cautiously interpreted because of several limitations in this meta-analysis of observational studies. A major limitation is the small number of studies that met our inclusion criteria. Additionally, analyzed results were from observational studies, which could contain potential confounders from factors in selected populations, such as age, gender, comorbidities, and prolonged hospitalization that might affect the risk of infection and having sepsis. Studies that measured serum 25(OH)D on admission or after hospitalization may not represent pre-illness vitamin D level. The vitamin D level could be underestimated from severe illness, or overestimate from vitamin D supplementation. We can assume that vitamin D level measuring before admission (at least 7 days) is not affected by critical illness. It is also a limitation to prevent sepsis by keeping optimal or normal vitamin D level in general population. It may also be difficult to normalize vitamin D in critically-ill patients.

Conclusions
In conclusion, we confirm previous study findings that vitamin D deficiency by having serum 25(OH)D less than 15-20 ng/mL is associated with higher chance of sepsis. Larger prospective observational studies that measure vitamin D level before critical illness are required to determine the causal relationship of sepsis. Further randomized controlled trials are needed to determine the role of vitamin D normalization before or during critical illness, and to investigate whether it can prevent infection or improve clinical outcomes in infected organ systems.

Additional file
Additional file 1: Search methodology. Details of the PubMed/MEDLINE, EMBASE, and CENTRAL database searches.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SU conceived of the study, searched the literature, assessed the quality of the studies, and drafted the manuscript. AS assessed the quality of the studies, performed the statistical analysis, and drafted the manuscript. NP participated in the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank you Mathew Roslund for validation of the search.
26. Braun AB, Litonjua AA, Moromizato T, Gibbons FK, Giovannucci E, Christopher KB. Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill. Crit Care Med. 2012;40(12):3170–9.

27. Matthews LR, Ahmed Y, Wilson KL, Griggs DD, Danner OK. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am J Surg. 2012;204:37–43.

28. Amrein K, Zajic P, Schnied C, Waltendorfer A, Fruhwald S, Holl A, et al. Vitamin D status and its association with season, hospital and sepsis mortality in critical illness. Crit Care. 2014;18(2):R47.

29. Nguyen HB, Eshete B, Lau KHW, Sai A, Villain M, Baylink D. Serum 1,25 Dihydroxyvitamin D: An Outcome Prognosticator in Human Sepsis. PLoS One. 2013;8(5):e64348.

30. Rech MA, Hunsaker T, Rodriguez J. Deficiency in 25-hydroxyvitamin D and 30-day mortality in patients with severe sepsis and septic shock. Am J Crit Care. 2014;23(5):e72–9.

31. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol. 2004;215:31–8.

32. Zhang H, Shih DQ, Zhang X. Mechanisms underlying effects of 1,25-Dihydroxyvitamin D3 on the TH17 cells. Eur J Microbiol Immunol. 2013;3(4):237–40.

33. Sun J. Vitamin D, and mucosal immune function. Curr Opin Gastroenterol. 2010;26(6):591–5.

34. Van Den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab. 2003;88:4623–32.

35. Mata-Granados JM, Vargas-Vasserot J, Ferreiro-Vera C, de Castro MDL, Pavon RG, Quesada Gomez JM. Evaluation of vitamin D endocrine system (DES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. J Steroid Biochem Mol Biol. 2010;121:452–5.

36. Amrein K, Sourij H, Wagner G, Holl A, Pieber TR, Smolle KH, et al. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. Crit Care. 2011;15:R104.

37. Vargas-Vasserot J, Mata-Granados JM, Luque De Castro M, Guerrero Pavon R, Quesada Gomez J. 25-hydroxyvitamin D3 treatment normalize the vitamin D status and the innate immune response mediated by cathelicidin in critically ill patients. Bone. 2011;48:5146–7.

38. Arnein K, Schnied C, Holl A, Riedl R, Christopher KB, Pachler C, Urbanic Purkart T, Waltendorfer A, Munch A, Warnkross H, Stojakovic T, Bisping E, Toller W, Smolle KH, Berghold A, Pieber TR, Dobsig H. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: The VITdAL-ICU Randomized Clinical Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. JAMA. 2014;312(15):1520-30.